FRIDAY, Jan. 10, 2025 (HealthDay News) — The machine learning system SCORPIO can predict patient outcomes with immune checkpoint inhibitor (ICI) therapy across diverse cancer types and health care settings, according to a study published online Jan. 6 in Nature Medicine.
Seong-Keun Yoo, Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues developed and evaluated SCORPIO utilizing routine blood tests and clinical characteristics from 9,745 ICI-treated patients across 21 cancer types. SCORPIO was trained on data from 1,628 patients across 17 cancer types and tested in internal test sets made up of 2,511 patients across 19 cancer types. External validation was performed on 10 global phase 3 trials with 4,447 patients across six cancer types and in a real-world cohort from Mount Sinai…